Vectibix (panitumumab) Market Report 2026

Vectibix (panitumumab) Market Overview

• The Vectibix (panitumumab) market growth in the historic period has been driven by approval for metastatic colorectal cancer, proven egfr inhibition efficacy • Market expansion is supported by growth in precision medicine adoption, increasing cancer diagnostics • Growth Driver: Rising Prevalence Of Colorectal Cancer To Drive Growth Of Vectibix (Panitumumab) Market • Market Trend: Advancements In Molecular Diagnostics With Companion Diagnostic Kits Enhancing Personalized Treatment In The Vectibix (Panitumumab) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vectibix (panitumumab) Market?

Vectibix (panitumumab) is a monoclonal antibody used in cancer treatment, specifically for metastatic colorectal cancer (mCRC). It works by targeting the epidermal growth factor receptor (EGFR), which is a protein found on the surface of some cancer cells. Panitumumab binds to EGFR and prevents the receptor from being activated by natural growth factors, thus inhibiting the signaling pathways that promote cell division and tumor growth. The main types of vectibix (panitumumab) distribution channels include hospital pharmacies and online pharmacies. Hospital pharmacies are pharmacies located within hospitals or healthcare facilities that provide medications to inpatients and outpatients as part of integrated medical care. It is used for colorectal cancer treatment and other cancer treatments by various end-users, including hospitals, clinics, and ambulatory surgical centers.

What Is The Vectibix (panitumumab) Market Growth Forecast?

The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $2 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growth in precision medicine adoption, increasing cancer diagnostics, expansion into additional cancer therapies, rising oncology healthcare spending, improved patient stratification. Major trends in the forecast period include increased use of targeted egfr therapies, expansion of precision oncology treatments, rising biomarker based patient selection, hospital based monoclonal antibody adoption, combination therapy use in advanced cancers.

What Are The Drivers Of The Vectibix (panitumumab) Market?

The increasing prevalence of colorectal cancer is expected to propel the growth of the vectibix (panitumumab) market going forward. Colorectal cancer refers to a type of cancer that starts in the colon or rectum, often developing from precancerous polyps. The rising prevalence of colorectal cancer is due to unhealthy lifestyle habits, as poor diet, lack of exercise, and obesity increase the risk of polyp formation and cancer development. Vectibix (panitumumab) is a monoclonal antibody that targets and inhibits the epidermal growth factor receptor (EGFR), which helps slow tumor growth and progression in patients with wild-type KRAS tumors, thus offering an effective therapeutic option for those who have not responded to conventional chemotherapy treatments. For instance, in February 2025, according to the American Cancer Society, a US-based nonprofit organization, the estimated number of new colorectal cancer cases was 154,270, an increase from 152,810 cases in 2024. Therefore, the increasing prevalence of colorectal cancer is expected to propel the growth of the vectibix (panitumumab) industry. The rising demand for personalized medicine is expected to propel the growth of the vectibix (panitumumab) market going forward. Personalized medicine is an approach to healthcare that customizes treatments and strategies based on the unique characteristics, needs, and preferences of each patient. The rising personalized medicine is due to due to advancements in genomic technologies, which enable the precise identification of genetic variations and tailored treatments for individuals. Vectibix (panitumumab) is used for personalized medicine by targeting the epidermal growth factor receptor (EGFR) on cancer cells, enabling tailored treatment for patients with metastatic colorectal cancer whose tumors express wild-type EGFR, thereby optimizing therapeutic efficacy and minimizing unnecessary side effects based on individual genetic profiles. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising demand for personalized medicine is driving th e growth of the vectibix (panitumumab) industry.

Key Players In The Global Vectibix (panitumumab) Market

Major companies operating in the vectibix (panitumumab) market are Amgen Inc.

Global Vectibix (panitumumab) Market Trends and Insights

Major companies operating in the vectibix (panitumumab) market are focusing on developing advanced companion diagnostics to enable targeted therapies, improve treatment efficacy, and ensure patient safety. Companion diagnostics refer to tests that provide essential information for the safe and effective use of a corresponding therapeutic product. For instance, in October 2023, EntroGen Inc., a US-based biotechnology company, received the U.S. Food and Drug Administration (FDA) approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab). The CRCdx RAS mutation detection kit is a unique molecular diagnostic tool that represents a significant advancement in precision medicine for colorectal cancer (CRC) patients. It is the first real-time PCR-based test in the U.S. to receive premarket approval (PMA) and fully meet the biomarker identification requirement for Vectibix. This innovative kit is designed to accurately detect mutations in KRAS and NRAS exons 2, 3, and 4, offering high sensitivity and specificity. It enables clinicians to efficiently identify patients most likely to benefit from vectibix therapy, minimizing unnecessary side effects and treatment costs.

What Defines the Vectibix (panitumumab) Market?

The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vectibix (panitumumab) Market Report 2026?

The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.